Shots:

• The P-lll JADE REGIMEN study involves assessing of Abrocitinib (100/ 200mg) vs PBO in 1233 patients aged ≥ 12 yrs. in a ratio (1:1:1) with mod. to sev. AD following response to initial open-label induction treatment with abrocitinib (200mg)
• Result: The study met its 1EPs i.e. probability of not experiencing a flare @52wks. (81.1%- 57.4% vs 19.1%) and 2EPs i.e. patients maintain an IGA response of clear or almost clear relative
• Following an initial 12wks. induction treatment phase- fewer patients experienced a flare at any point in the trial @40wks. Abrocitinib is a JAK inhibitor- which modulates multiple cytokines involved in the pathophysiology of AD- including IL-4- IL-13- IL-31- IL-22- and TSLP

­  Ref: Pfizer | Image: Forbes